Scancell (LON:SCLP) Trading Up 7% on Insider Buying Activity

Scancell Holdings plc (LON:SCLP)’s share price was up 7% during mid-day trading on Wednesday after an insider bought additional shares in the company. The stock traded as high as GBX 10.43 ($0.14) and last traded at GBX 9.90 ($0.13). Approximately 1,065,551 shares traded hands during trading, an increase of 21% from the average daily volume of 878,498 shares. The stock had previously closed at GBX 9.25 ($0.12).

Specifically, insider Martin Diggle acquired 44,944 shares of the company’s stock in a transaction that occurred on Tuesday, May 20th. The shares were bought at an average price of GBX 9 ($0.12) per share, with a total value of £4,044.96 ($5,424.38).

Scancell Stock Performance

The business has a 50-day moving average of GBX 9.35 and a two-hundred day moving average of GBX 10.24. The company has a market cap of £102.54 million, a P/E ratio of -15.18 and a beta of 0.35. The company has a debt-to-equity ratio of -566.79, a current ratio of 3.42 and a quick ratio of 13.01.

About Scancell

Scancell (LSE:SCLP) is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer. We aim to translate our innovation and creativity into increased and durable responses in patients without compromising safety, addressing hard-to-treat cancers.

Scancell has developed a pipeline of ‘off-the-shelf’ vaccines to induce immune responses and highly tumour specific monoclonal antibodies to redirect immune cells or drugs.